A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

NCT03912064 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
Chronic Myelomonocytic Leukemia
Myelofibrosis

Interventions

DRUG: Ipilimumab
BIOLOGICAL: CD25hi Treg depleted DLI

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]